R&D | March 20, 2026
NIPER Raebareli–Roche tie-up signals big push for India’s pharma innovation future
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
The partnership is designed to close the gap between classroom learning and real-world pharmaceutical practice
Cadila Pharmaceuticals’ journey has been marked by several milestones, including the development of indigenous formulations, expansion into global markets, and the creation of robust manufacturing and R&D capabilities
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
Nadda underlined that India’s policy framework is aligned with this transformation
The MoU lays the groundwork for deep academic and research collaboration in pharmaceutical technologies
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Leaders from science, policy, industry, and investment came together in New Delhi to examine how alignment across the biotechnology value chain can turn innovation into outcomes at scale
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Subscribe To Our Newsletter & Stay Updated
